Key clinical point: For almost half of patients with nonalcoholic steatohepatitis, bariatric surgery does not resolve severe fibrosis.
Major finding: At follow-up liver biopsy, 45% of patients had persistent severe fibrosis despite losing an average of one-quarter of their baseline bodyweight.
Study details: A retrospective and observational study involving 868 patients with nonalcoholic steatohepatitis who underwent bariatric surgery.
Disclosures: The investigators disclosed relationships with Allergan, Boehringer Ingelheim, Novo Nordisk, and others.
Pais R et al. The Liver Meeting 2019, Abstract 66.